Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Managing advanced phase chronic myeloid leukemia

Posted by on Dec 24, 2019 in Leukemia | 0 comments

In a nutshell This study reviewed treatment options for advanced phase chronic myeloid leukemia. This study concluded that managing advanced phase chronic myeloid leukemia remains challenging and treatment options include tyrosine kinase inhibitors, chemotherapy, and transplant.  Some background Chronic myeloid leukemia (CML) can be...

Read More

Searching for patients with relapsed or unresponsive chronic lymphocytic leukemia to test an immune cell-stimulating treatment

Posted by on Dec 19, 2019 in Leukemia | 0 comments

In a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells.  The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH,...

Read More

Evaluating pembrolizumab for patients with primary mediastinal large B-cell lymphoma that has come back or stopped responding to treatment

Posted by on Nov 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with primary mediastinal large B-cell lymphoma (PMBCL) that has come back or stopped responding to treatment. This study concluded that pembrolizumab was safe and effective for these patients. Some background PMBCL is one rare and aggressive type...

Read More

How effective and safe is acalabrutinib compared to other treatments for patients with mantle cell lymphoma?

Posted by on Nov 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness and safety of acalabrutinib (Calquence) to other targeted therapies for patients with mantle cell lymphoma (MCL). The authors found that acalabrutinib was just as safe and more effective for these patients. Some background MCL is a type of non-Hodgkin's lymphoma treated in...

Read More

Encorafenib, cetuximab and binimetinib combined treatment improves survival of patients with advanced colorectal cancer

Posted by on Oct 31, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated whether treatment with encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) combined would increase survival in advanced colorectal cancer (CRC). Researchers suggested that this combined therapy increases the survival of patients with metastatic (spread to other parts of the...

Read More

Evaluating a triplet regimen for patients with relapsed or refractory MM after lenalidomide therapy

Posted by on Oct 1, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study examined if PBD (pomalidomide, bortezomib, dexamethasone) was safe and effective in patients with multiple myeloma after lenalidomide (Revlimid) treatment. The authors concluded that pomalidomide improved survival without tumor growth or spread but increased side effects. Some background...

Read More

Looking for patients with relapsed or unresponsive multiple myeloma to try allogeneic CAR-T cell therapy

Posted by on Sep 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial is evaluating the safety and effectiveness of allogeneic CAR-T cell therapy (ALLO-715) in patients with multiple myeloma (MM) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This trial is recruiting in Denver, CO. The details Chimeric...

Read More

Nivolumab in previously treated advanced non-small cell lung cancer – what is the long-term outlook for survival?

Posted by on Sep 16, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated survival rates in advanced non-small cell lung cancer (NSCLC) after nivolumab (Opdivo) treatment.  They found that nivolumab was associated with longer survival time in patients that responded to treatment.  Some background Lung cancer (LC) is one of the most common cancers worldwide. Non-small...

Read More